Published in 2014 - Ann Oncol (2014) doi: 10.1093/annonc/mdu123
Authors: B. Besse, A. Adjei, P. Baas, P. Meldgaard, M. Nicolson, L. Paz-Ares, M. Reck, E.F. Smit, K. Syrigos, R. Stahel, E. Felip, S. Peters
This report from the 2nd ESMO Consensus Conference on Lung Cancer covers all patients (regardless of NSCLC mutational status): chemotherapy in asymptomatic patients, anti-angiogenic treatment, to switch or to continue maintenance treatment, elderly patients, and systemic treatment for bone metastases, NSCLC aberrations: first-line treatment for EGFR mutated and ALK rearranged NSCLC, optimal management of brain metastases at diagnosis, and recommendations for later lines, and emerging biomarkers and secondary resistance: re-biopsy and treatment options for patients with ROS1, RET, BRAF or HER2 alterations after standard treatment.